Literature DB >> 24490027

Difference of perceptions and evaluation of cognitive dysfunction in major depressive disorder patients across psychiatrists internationally.

Emna El Hammi1, Jennifer Samp2, Cécile Rémuzat1, Jean-Paul Auray3, Michel Lamure3, Samuel Aballéa1, Amna Kooli1, Kasem Akhras2, Mondher Toumi4.   

Abstract

BACKGROUND: Many studies have suggested that major depressive disorder (MDD) is often associated with cognitive dysfunction. Despite this, guidance addressing assessment of cognitive dysfunction in MDD is lacking. The aim of this study was to examine psychiatrists' perceptions and evaluation of cognitive dysfunction in routine practice in MDD patients across different countries.
METHOD: A total of 61 psychiatrists in the US, Germany, France, Spain, Hong Kong, and Australia participated in an online survey about perceptions of cognitive dysfunction in MDD patients, evaluation of cognition and instruments used in cognitive evaluation.
RESULTS: Most psychiatrists reportedly relied on patient history interviews for cognitive evaluation (83% in France and approximately 60% in the USA, Germany, Australia and Hong Kong). The remainder used a cognitive instrument or a combination of cognitive instrument and patient history interview for assessment. Of those using instruments for cognitive assessment, only nine named instruments that were appropriate for cognitive evaluation. The remainder reported other clinical measures not intended for cognitive evaluation.
CONCLUSIONS: Overall, psychiatrists in routine clinical practice value the assessment of cognitive in MDD. However, there is a lack of standardization in these assessments and misconceptions regarding proper assessment.

Entities:  

Keywords:  cognitive dysfunction; cognitive instruments; major depressive disorder; neuropsychological tests

Year:  2014        PMID: 24490027      PMCID: PMC3896134          DOI: 10.1177/2045125313507946

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN: 2045-1253


  21 in total

1.  NIMH-MATRICS survey on assessment of neurocognition in schizophrenia.

Authors:  Robert S Kern; Michael F Green; Keith H Nuechterlein; Bi-Hong Deng
Journal:  Schizophr Res       Date:  2004-12-15       Impact factor: 4.939

2.  Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Wai Tat Chiu; Olga Demler; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

3.  Neurocognition in depression: patients on and off medication versus healthy comparison subjects.

Authors:  C Thomas Gualtieri; Lynda G Johnson; Kenneth B Benedict
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2006       Impact factor: 2.198

4.  Evidence-based health policy--lessons from the Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Science       Date:  1996-11-01       Impact factor: 47.728

5.  Persistent cognitive impairment in depression: the role of psychopathology and altered hypothalamic-pituitary-adrenocortical (HPA) system regulation.

Authors:  Simone Reppermund; Josef Zihl; Susanne Lucae; Sonja Horstmann; Stefan Kloiber; Florian Holsboer; Marcus Ising
Journal:  Biol Psychiatry       Date:  2006-12-22       Impact factor: 13.382

6.  Executive deficits in elderly patients with major unipolar depression.

Authors:  Sophie Baudic; Catherine Tzortzis; Gianfranco Dalla Barba; Latchezar Traykov
Journal:  J Geriatr Psychiatry Neurol       Date:  2004-12       Impact factor: 2.680

7.  Altered empathic responding in major depressive disorder: relation to symptom severity, illness burden, and psychosocial outcome.

Authors:  Andrée M Cusi; Glenda M Macqueen; R Nathan Spreng; Margaret C McKinnon
Journal:  Psychiatry Res       Date:  2011-05-17       Impact factor: 3.222

8.  Persistence of cognitive impairment in geriatric patients following antidepressant treatment: a randomized, double-blind clinical trial with nortriptyline and paroxetine.

Authors:  Robert D Nebes; Bruce G Pollock; Patricia R Houck; Meryl A Butters; Benoit H Mulsant; Michelle D Zmuda; Charles F Reynolds
Journal:  J Psychiatr Res       Date:  2003 Mar-Apr       Impact factor: 4.791

9.  The frequency of cognitive impairment in patients with anxiety, depression, and bipolar disorder: an unaccounted source of variance in clinical trials.

Authors:  C Thomas Gualtieri; Dexter W Morgan
Journal:  J Clin Psychiatry       Date:  2008-07       Impact factor: 4.384

10.  Cognitive performance in tests sensitive to frontal lobe dysfunction in the elderly depressed.

Authors:  B C Beats; B J Sahakian; R Levy
Journal:  Psychol Med       Date:  1996-05       Impact factor: 7.723

View more
  5 in total

1.  Italian neurologists' perception on cognitive symptoms in major depressive disorder.

Authors:  G Neri; C Serrati; P Zolo; N Cataldo; C Ripellino
Journal:  Neurol Sci       Date:  2016-05-07       Impact factor: 3.307

Review 2.  Cognitive Dysfunction in Major Depressive Disorder. A Translational Review in Animal Models of the Disease.

Authors:  Flavie Darcet; Alain M Gardier; Raphael Gaillard; Denis J David; Jean-Philippe Guilloux
Journal:  Pharmaceuticals (Basel)       Date:  2016-02-17

3.  Cognitive Dysfunction in Asian Patients with Depression (CogDAD): A Cross-Sectional Study.

Authors:  Srisurapanont Manit; Mok Yee Ming; Yang Yen Kuang; Chan Herng-Nieng; Della Constantine D; Zainal Nor Zuraida; Jambunathan Stephen; Amir Nurmiati; Kalita Pranabi
Journal:  Clin Pract Epidemiol Ment Health       Date:  2017-10-31

4.  Improvement of postoperative cognitive dysfunction and attention network function of patients with ischemic cerebrovascular disease via dexmedetomidine.

Authors:  Jingchao Zhang; Guoliang Wang; Fangxiang Zhang; Qian Zhao
Journal:  Exp Ther Med       Date:  2018-01-30       Impact factor: 2.447

5.  Assessment of current clinical practices for major depression in Japan using a web-based questionnaire.

Authors:  Hikaru Hori; Kentaro Yamato
Journal:  Neuropsychiatr Dis Treat       Date:  2019-10-01       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.